Objective: Acute myocardial infarction (AMI) remains a major cause of death and β-blockers are known to reduce long-term mortality in post-AMI patients. We sought to determine whether patients receiving β-blockers acutely (within 72 h) following AMI had a lower mortality rate at 6 weeks than patients receiving placebo. Methods: We conducted a systematic review of randomized controlled clinical trials that assessed 6-week mortality and compared β-blockers with placebo in patients randomized within the first 72 hours following AMI. We searched these databases: MEDLINE (1966MEDLINE ( -2006, EMBASE (1980EMBASE ( -2007, Cochrane Central Register of Controlled Trials, Health Star (1966Star ( -2007, Cochrane Database for Systematic Reviews, ACP Journal Club (1991-2007, Database of Abstracts of Reviews of Effect (< 1st quarter 2007) and Conference Papers Index . Two blinded reviewers extracted the data and rated study quality using the Jadad score and the adequacy of allocation concealment score, which was adopted by the Cochrane group. We calculated pooled odds ratios (ORs) using a random effect model and performed sensitivity analyses to explore the stability of the overall treatment effect. Results: We included 18 studies (13 were rated high-quality) with 74 643 enrolled participants and had 5095 deaths. Compared with placebo, adding β-blockers to other interventions within 72 hours after AMI did not result in a statistically significant reduction in 6-week mortality (OR 0.95, 95% confidence interval [CI] 0.90-1.01). When restricted to high quality studies, the OR for 6-week mortality reduction was 0.96 (95% CI 0.91-1.02). We found similar results including studies that enrolled patients within 24 hours after AMI. However, a subgroup analysis that excluded high-risk patients with Killip class III and above showed that β-blockers resulted in a significant reduction in short-term mortality (OR 0.93,. Conclusion: Acute intervention with β-blockers does not result in a statistically significant shortterm survival benefit following AMI but may be beneficial for low-risk (Killip class I) patients. RÉSUMÉObjectif : L'infarctus aigu du myocarde (IAM) demeure une importante cause de décès et il est reconnu que les β-bloquants réduisent la mortalité à long terme chez les patients qui ont subi un
Cranial computed tomography (CT) of the head is widely used in the emergency department 24 h a day. We compared the accuracy of CT head interpretation between staff emergency physicians (EPs) and neuroradiologists. We conducted a health records review of patients who required head CT in the emergency department. Two independent reviewers rated disagreement as clinically normal, significant, or clinically insignificant findings using published definition criteria. We calculated concordance and prepared descriptive and kappa statistics with 95% confidence intervals using SAS 9.1 software. We included 442 for this study. CT heads were classified as: normal or nonacute 81.5% (360 cases), insignificant 3.8% (17 cases), and significant 14.7% (65 cases). The weighted kappa for agreement was 0.83 (95% confidence interval 0.76-0.90). None of these patients had adverse outcomes related to EP misinterpretation of the CT head. In conclusion, clinically important findings on CT head are not commonly missed by our EPs and patients rarely have inappropriate disposition.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.